Theravance Biopharma, Inc. (TBPH) EVP Sells $451,395.90 in Stock
Theravance Biopharma, Inc. (NASDAQ:TBPH) EVP Bradford J. Shafer sold 14,670 shares of Theravance Biopharma stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $30.77, for a total transaction of $451,395.90. Following the completion of the transaction, the executive vice president now directly owns 134,327 shares in the company, valued at $4,133,241.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Theravance Biopharma, Inc. (NASDAQ TBPH) opened at 31.43 on Monday. Theravance Biopharma, Inc. has a 12-month low of $23.15 and a 12-month high of $43.44. The company has a 50-day moving average of $30.03 and a 200 day moving average of $35.19. The company’s market cap is $1.69 billion.
Hedge funds have recently modified their holdings of the stock. QS Investors LLC bought a new stake in Theravance Biopharma during the second quarter valued at about $100,000. Ameritas Investment Partners Inc. boosted its position in Theravance Biopharma by 1,494.3% during the first quarter. Ameritas Investment Partners Inc. now owns 3,635 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 3,407 shares in the last quarter. Aperio Group LLC bought a new stake in Theravance Biopharma during the second quarter valued at about $205,000. BNP Paribas Arbitrage SA boosted its position in Theravance Biopharma by 570.7% during the second quarter. BNP Paribas Arbitrage SA now owns 5,151 shares of the biopharmaceutical company’s stock valued at $205,000 after purchasing an additional 4,383 shares in the last quarter. Finally, Amalgamated Bank bought a new stake in Theravance Biopharma during the second quarter valued at about $214,000. 84.54% of the stock is currently owned by institutional investors.
Several analysts recently weighed in on TBPH shares. Zacks Investment Research upgraded shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a report on Tuesday, September 5th. Evercore ISI started coverage on shares of Theravance Biopharma in a report on Wednesday, August 16th. They issued an “outperform” rating and a $45.00 price target on the stock. Cantor Fitzgerald set a $55.00 price target on shares of Theravance Biopharma and gave the company a “buy” rating in a report on Wednesday, August 16th. BidaskClub cut shares of Theravance Biopharma from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd. Finally, Needham & Company LLC reiterated a “buy” rating on shares of Theravance Biopharma in a report on Wednesday, August 2nd. Four equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $41.63.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Stock Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related stocks with our FREE daily email newsletter.